Classical Philadelphia chromosome-negative myeloproliferative neoplasms are a group of closely related myeloid disorders with different histologic features and clinical presentations at an early stage, but all later develop into a similar fibrotic stage with variable risk of acute transformation. The significance of 3q26.2/EVI1 rearrangement has been well recognized in acute myeloid leukemia, myelodysplastic syndrome, and chronic myeloid leukemia. However, the clinical importance of 3q26.2/EVI1 rearrangement in classical Philadelphia chromosome-negative myeloproliferative neoplasms is unknown. Here we reported 15 patients with classical Philadelphia chromosome-negative myeloproliferative neoplasms showing 3q26.2 rearrangement, including inv (3)(q21q26.2) (n = 6), t(3;21)(q26.2;q22)(n = 4), t(3;3)(q21;q26.2)(n = 3), inv(3)(q13.3q26.2)(n = 1), and t(3;12)(q26.2; p13)(n = 1). In addition to 3q26.2 rearrangement, 9 of 15 cases had other concurrent karyotypical abnormalities, including -7/7q-and -5/5q-. There were 8 men and 7 women with a median age of 59 years (range, 35-79 years) at initial diagnosis of myeloproliferative neoplasms: 8 patients had primary myelofibrosis, 4 had polycythemia vera, and 3 had essential thrombocythemia. JAK2 V617F mutation was detected in 8/14 patients, including 4/4 with polycythemia vera. The median interval from the initial diagnosis of myeloproliferative neoplasms to the detection of 3q26.2 rearrangement was 44 months (range, 1-219 months). At time of emergence of 3q26.2 rearrangement, 11 patients were in blast phase and 2 patients had increased blasts (6-19%). Dyspoiesis, predominantly in megakaryocytes, were detected in all patients with adequate specimens at time of 3q26.2 rearrangement. Following 3q26.2 rearrangement, 12 patients received chemotherapy, but none of them achieved complete remission. Of 14 patients with follow-up information, all died with a median overall survival time of only 3 months (range 0-14 months) after the emergence of 3q26.2 rearrangement. In summary, 3q26.2 rearrangement in classical Philadelphia chromosome-negative myeloproliferative neoplasms is associated with other concurrent cytogenetic abnormalities, a rapid disease progression and blast transformation, a poor response to chemotherapy and a dismal prognosis. Modern Pathology (2017) 30, 940-951;
somatic mutations of JAK2, MPL, and CALR are critical events in the initial pathogenesis of many cases of Philadelphia chromosome-negative myeloproliferative neoplasms. 2, 7, 8 However, these mutations do not provide a complete explanation for disease progression. Cytogenetic abnormalities are an essential part of prognostic systems, and their prognostic relevance has been well recognized in myeloid malignancies, including acute myeloid leukemia, myelodysplastic syndrome, and chronic myeloid leukemia. [9] [10] [11] [12] Although most chromosomal abnormalities observed in Philadelphia chromosome-negative myeloproliferative neoplasms are nonspecific, cytogenetic analysis is still recommended as part of the diagnostic work-up. Cytogenetic abnormalities occur in up to 30% patients of primary myelofibrosis, 20% of polycythemia vera, and 5-10% of essential thrombocythemia. 13 The potential role of cytogenetic alterations in the progression of Philadelphia chromosome-negative myeloproliferative neoplasms is unknown.
The MDS1 and ectotropic virus integration site 1 (EVI1) complex (MECOM) locus is located in chromosomal band 3q26.2, giving rise to two major mRNA and protein species, EVI1 and MDS1. Chromosomal rearrangements involving the 3q26.2 locus reported previously include inv(3)(q21q26.2), t(3;3)(q21;q26.2), t(3;21)(q26.2;q22), t(3;12)(q26.2; p13), and other rare reciprocal translocations involving 3q26.2, and have been recognized in acute myeloid leukemia, myelodysplasia syndrome, and accelerated and blast phases of chronic myeloid leukemia. These chromosomal aberrations involve the EVI1 oncogene, which encodes an essential transcription factor for the regulation of selfrenewal of hematopoietic stem cells. 14, 15 Acute myeloid leukemia with inv(3)/t(3;3) is known to be associated with atypical megakaryocytes, multilineage dysplasia, and an unfavorable prognosis, and is listed among acute myeloid leukemia with recurrent cytogenetic abnormalities in current WHO classification. 3, 10, 16 Myelodysplastic syndrome patients with inv(3;3)/t(3;3) have a poor prognosis similar to acute myeloid leukemia patients with inv (3;3)/t(3;3), regardless of the blast percentage. 9 Similar to inv(3;3)/t(3;3), t(3;21) is also associated with a poor clinical outcome in acute myeloid leukemia and myelodysplastic syndrome. A recent large study based on 2013 chronic myeloid leukemia patients showed that chronic myeloid leukemia patients with 3q26.2 rearrangement have a minimal response to tyrosine kinase inhibitor therapy, a high rate of blastic transformation, and a poor overall survival. 11, 12 To date, few, if any, studies have focused on 3q26.2 rearrangement at the cytogenetic level in patients with classical Philadelphia chromosomenegative myeloproliferative neoplasms. In this study, we described the clinicopathologic features of 15 patients of classical Philadelphia chromosomenegative myeloproliferative neoplasms with 3q26.2 rearrangement. Similar to the role of 3q26.2 rearrangement in the progression of chronic myeloid leukemia, our data demonstrated that 3q26.2 arrangement in classical Philadelphia chromosomenegative myeloproliferative neoplasms is associated with a rapid disease progression, a treatment resistance and a dismal outcome.
Materials and methods

Patient Selection
Cases of classical Philadelphia chromosomenegative myeloproliferative neoplasms diagnosed in our institution since 1998 through 2015 were reviewed to identify those with 3q26.2 rearrangement. Patients' clinical information including treatment regimens, disease progression, and follow-up data were obtained. This study was approved by the Institutional Review Board at the University of Texas MD Anderson Cancer Center.
Morphologic Studies
Bone marrow core biopsies were prepared following formalin fixation and decalcification, and were stained with hematoxylin and eosin. Bone marrow aspirate and touch imprint smears as well as peripheral blood smear were stained with WrightGiemsa stain. Bone marrow differential count was performed by counting 500 nucleated cells from aspirate smears and/or 300 nucleated cells from touch imprint smears. Immunohistochemistry and special stains, including reticulin and trichrome stains, were performed on the biopsy specimens.
Immunohistochemistry and Flow Cytometric Analyses
Immunohistochemical studies were performed using formalin-fixed paraffin-embedded tissue sections according to standard protocols. The antibodies used included CD34 (1:40; BD Biosciences, San Jose, CA, USA), CD61 (1:100; Cell Marque, Rocklin, CA, USA), CD117 (1:100), myeloperoxidase (1:6000), and TdT (1:50; Dako, Carpinteria, CA, USA). Flow cytometry immunophenotypic analysis was performed using standard multicolor analysis which evolved substantially during the study interval . The panel of antibodies included reagents  specific for CD2, CD3, CD4, CD5, CD7, CD10, CD11c,  CD13, CD15, CD19, CD20, CD22, CD25, CD30, CD34,  CD38, CD41, CD45, CD61, CD79b, CD117, CD123 , and HLA-DR (Becton-Dickinson, Biosciences, San Jose, CA, USA).
Cytogenetic Studies
Conventional chromosomal analysis was performed on G-banded metaphase cells prepared from unstimulated bone marrow aspirate cultures (24 and 48 h) using standard methods. The karyotype was reported according to the current International System for Philadelphia chromosome-negative myeloproliferative neoplasms Z Hu et al Human Cytogenetic Nomenclature. 17 Florescence in situ hybridization (FISH) was performed on freshly harvested aspirate smears or cultured bone marrow cells according to the standard protocol. The KREATECH MECOM (EVI1) (SO/SG) FISH probe (Leica Biosystems, Buffalo Grove, IL, USA) was used in our present study. A total of 200 interphase nuclei were analyzed.
Molecular Studies
All molecular studies were performed on the bone marrow aspirate samples. Quantitative real-time reverse transcriptase polymerase chain reaction (PCR) analysis was performed for the BCR-ABL1 fusion transcripts e13a2 (b2a2), e14a2 (b3a2) and e1a2. CEBPA (CCAAT/enhancing binding proteinalpha) mutation was detected by using PCR-based DNA sequencing analysis. In recent cases, nextgeneration sequencing-based analysis for the detection of somatic mutations in the coding sequence of a total of 28 genes (including DNMT3A, JAK2, NPM1, FLT3, MPL, NRAS, KRAS, KIT, IDH1, IDH2, and TP53) was performed on the DNA extracted from the aspirate samples.
International Prognostic Index
Dynamic International Prognostic Scoring System (DIPSS) and DIPSS-plus were used to estimate prognosis in patients with Philadelphia chromosome-negative myeloproliferative neoplasms following the emergence of 3q26.2 rearrangement. The clinical characteristics in the DIPSS model include age, constitutional symptoms, white blood cell count, hemoglobin, and blast count in peripheral blood. Besides DIPSS risk factors, the DIPSS-plus score also includes karyotype, transfusion dependency, and platelet count. In these models, the prognosis is based on a 0-6-point scoring system. The DIPSS-plus score and its corresponding prognosis are listed below: score 0: low risk, estimated median survival 180 months; score 1: intermediate-1 risk, estimated median survival 80 months; score 2-3: intermediate-2 risk, estimated median survival 35 months; score 4 or more: high risk, estimated median survival 16 months. 18 
Results
Clinical Characteristics
A total of 1842 patients diagnosed with classical Philadelphia chromosome-negative myeloproliferative neoplasms since 1998 through 2015 had karyotyping information available, and 15 (0.8%) of them were identified to have 3q26.2 rearrangement. There were 8 men and 7 women with a median age of 59 years (range, 35-79 years) at the time of initial diagnosis of myeloproliferative neoplasms. Eight patients had a diagnosis of primary myelofibrosis, 4 had polycythemia vera, and 3 had essential thrombocythemia. 3q26.2 rearrangement developed a median time of 44 months (range 1-219 months) after the initial diagnosis of myeloproliferative neoplasms ( Table 1 ). The median interval for the emergence of 3q26.2 rearrangement in primary myelofibrosis, polycythemia vera, and essential thrombocythemia was 30, 96, and 61 months, respectively.
Morphologic and Immunophenotypic Findings
At the time of detection of 3q26.2 rearrangement, dysplasia in one or multi-lineages was detected in all patients with bone marrow showing adequate cellularity for morphologic evaluation: dysgranulopoiesis in 6/14 (43%), dyserythropoiesis in 8/12 (67%), and dysmegakaryopoiesis in 13/13 (100%) patients (Table 2 ). Megakaryocytes were increased in 10 patients. Dysmegakaryopoiesis showed diverse morphology including small hyperchromatic, hypolobated/monolobated, or large atypical megakaryocytes ( Figure 1 ). The number and morphology of megakaryocytes were noted to change with the disease progression. Reticulin and trichrome stains were performed on bone marrow biopsy specimens in 14 patients: 6 patients had MF-3, 7 had MF-2, and 1 had MF-1. As an example, the histological findings of case #12 before and after 3q26.2 emergence are illustrated in Figure 2 .
At the time of detection of 3q26.2 rearrangement, 13 (87%) patients had increased blast count, ranging from 8% to 92%; 11/15 (73%) had blast phase (≥20% blasts in bone marrow or peripheral blood), 1 had accelerated phase (patient #8, 14% blasts), and 1 (patient #2) had 8% blasts in the bone marrow. Of note, patient #2 developed blast crisis 5 months after the emergence of 3q26.2 rearrangement (53% blasts in bone marrow; 44% in peripheral blood). Of the two patients (#9 and #15) who had no increase in blasts, patient #9 had an accelerated phase (12% blasts in bone marrow) 12 months after the emergence of 3q26.2 rearrangement.
Of the 13 patients with increased blasts, blasts in 12 patients (except patient #1) had myeloid phenotype. Patient #1 had one subset of blasts with erythroid differentiation and another subset with megakaryocytic differentiation. Five (5/12) patients had blasts with other lineage differentiation. For example, Patient #3 showed blasts with abundant CD61 expression indicating megakaryocytic differentiation. Patients #4, 7, 11, and 12 had blasts with CD4, CD14, and/or CD64 expression indicating monocytic differentiation. Interestingly, case #4 showed two blast populations, a predominant myeloblast population and a small population of blasts with aberrant expression of CD19 and CD22, indicating B-lymphoid lineage ( Table 2) . 
Cytogenetics and Molecular Findings
Rearrangements involving 3q26.2 locus were diverse in this cohort and included inv(3)(q21q26.2) (n = 6), t(3;21)(q26.2;q22)(n = 4), t(3;3)(q21;q26.2)(n = 3), inv (3)(q13.3q26.2)(n = 1), and t(3;12)(q26.2;p13) (n = 1; Table 3 ). The 3q26.2/EVI1 rearrangements were confirmed by FISH analyses in 4/4 patients (patients #2, 9, 11, and 12; Figure 3) . Nine of 15 patients had additional karyotypical abnormalities in the same clone of 3q26.2 rearragnements, including -7/7q-in 6 patients, -5/5q-in 5 patients, and -17 in 3 patients. 2) was present in a different subclone without t(3;3). Patient #7 had additional inv(9) (p11q12) in the clone of t(3;21), which is a chromosomal polypormorphism with no known clinical significance. JAK2 mutation analysis was performed in 14 patients, and was positive in 8 patients, including 4/4 (100%) patients with polycythemia vera, 2/3 (68%) patients with essential thrombocythemia, and 2/7 (29%) patients with primary myelofibrosis. Patient #12 had TP53 and DNMT3A mutations in addition to JAK2 mutation. FLT3 mutation was positive in 1 patient with primary myelofibrosis (patient #6). BCR-ABL1 was negative in 8/8 patients, and RAS mutation was negative in 6/6 patients.
Treatment and Outcome
Depending on the type of myeloproliferative neoplasms at initial diagnosis, patients received different treatment regimens. All patients except patient #3 received treatment before the detection of 3q26.2 rearrangement, including hydroxyurea in 12 patients and phlebotomies in 3 patients with polycythemia vera. After 3q26.2 rearrangement was detected, 12 patients received chemo-or targeted therapy, and in the remaining 3 patients, the treatment regimens were not known. The detailed treatment and followup are illustrated in Table 1 . Of the 12 patients who received known therapy regimens after the emergence of 3q26.2 rearrangement, 9 patients (patients #3, 5, 6, 7, 8, 10, 11, 12, and 14) had no response to treatment. The other 3 patients (patients #2, 9, and 13) had responses to some degree or relapse but similar poor outcome. Patient #2 received cladribine Philadelphia chromosome-negative myeloproliferative neoplasms plus low-dose ara-C alternating with decitabine for four cycles and achieved morphologic remission, but he developed relapsed disease soon and expired 10 months after 3q26.2 rearrangement was detected. Patient #9 received lestaurtinib, a multitargeted tyrosine kinase inhibitor, and showed significant reduction of splenomegaly and platelet counts, as well as reduction in her transfusion dependence, but she developed pancytopenia and expired 2 months later. Patient #13 received idarubicin, cytarabine and methylprednisone therapy and initially had significant reduction of blast count, but she developed pancytopenia and alveolar hemorrhage. She had relapsed disease and multi-organ failure and expired one month following 3q26.2 rearrangement.
Of 14 patients with follow-up information, none of the patients survived progressive disease and were eligible for stem cell transplantation. The median overall survival after the initial diagnosis of myeloproliferative neoplasms was 51 months (range, 7-220 months). The median survival times for primary myelofibrosis, polycythemia vera and essential thrombocythemia subgroups were 36, 104, and 106 months, respectively. Following 3q26.2 rearrangement, the patients had a median overall survival of only 3 months (range, 0-14 months). It seems that additional karyotypical abnormalities besides 3q26.2 rearrangement may have adverse impact on patient survival. Those with additional karyotypical abnormalities in the same clone of 3q26.2 rearrangement had a worse survival than those without (median: 3 months vs 7 months) although no statistical significance was reached (P = 0.25). There was statistically significant difference in the overall survival between patients with and without -17 (median: 1 month vs 4 months, P = 0.04). These three patients with -17 had a highly complex karyotype.
Prognosis in DIPSS and DIPSS-Plus Models
Prognostic scores were calculated in this study cohort by using DIPSS and DIPSS-plus models. Application of the DIPSS resulted in categorization Table 4) , with a predicted median overall survival of 35 months. By the DIPSSplus model, this cohort of patients were categorized into intermediate-2 risk (n = 2) and high-risk (n = 13), with a predicted median overall survival of 16 months. However, the actual median survival following 3q26.2 rearrangement in this cohort was only 3 months, markedly shorter than the overall survival predicted by both models, substantiating the dismal prognostic impact conferred by 3q26.2 rearrangement.
Discussion
In this study, we reported the clinicopathologic features of 15 patients with classical Philadelphia chromosome-negative myeloproliferative neoplasms showing 3q26.2 rearrangement. We found that 3q26.2 rearrangement was associated with a dismal outcome. At the time of 3q26.2 rearrangement, the vast majority of patients developed blastic transformation. None of the patients responded to therapy and all had a poor survival following 3q26.2 rearrangement. Philadelphia chromosome-negative myeloproliferative neoplasms
As mentioned above, 3q26.2 rearrangement has been identified in several types of myeloid neoplasms. Currently, 34 chromosomal rearrangements of 3q26.2 locus have been confirmed to have EVI1 involvement, including inv(3), t(3;3), t(3;21), and t(3;12). 7, 10, 14 The 3q26.2 rearrangement leads to EVI1 dysregulation, which can be achieved through two different mechanisms. In in(3)(q21q26.2) and t(3;3) (q21;q26.2), inappropriate expression of EVI1 is likely caused by the juxtaposition of regulatory sequences (enhancers or promoters). In recent studies, using inv(3)/t(3;3) as a model, it is found that 3q26.2 rearrangement repositions a distal GATA2 enhancer to activate and cause deregulation of EVI1 gene. 19, 20 In t(3;21)(q26.2;q22) and t(3;12) (q26.2;p13), EVI1 gene fuses with RUNX1 and ETV6, respectively, resulting in the formation of chimeric fusion transcripts. 10, [21] [22] [23] Similar to patients with other types of myeloid neoplasms with 3q26.2 rearrangement, patients with classical Philadelphia chromosome-negative myeloproliferative neoplasms showing 3q26.2 rearrangement have a poor outcome. The presence of 3q26.2 rearrangement in different types of myeloid neoplasms suggests a common pathogenic pathway leading to disease progression. This concept was previously dubbed as '3q26.2 syndrome,' which is associated with normal or elevated platelet counts with marked abnormalities of megakaryopoiesis and involvement of multiple hematopoietic lineages. 16, 24 Based on the studies of EVI1 in myeloid malignancies, the development of '3q26.2 syndrome' can be explained by a theoretical 'two-hit' process. The first hit is the primary neoplastic driver aberrations, transforming non-malignant cells to clonal neoplastic cells. In classical Philadelphia chromosomenegative myeloproliferative neoplasms, the molecular alterations including mutations of JAK2, MPL, and CALR can be the driver events. As the clonal progeny expands and disease burden increases, more mutations may occur, resulting in additional cytogenetic alterations that can be defined as 'second hit.' This second hit can produce an aggressive subclone with survival advantage and resistance to previous therapy. The event of 3q26.2 rearrangement can be regarded as a second hit of myeloid neoplasms.
The bone marrow of myelodysplastic syndrome/ acute myeloid leukemia patients with 3q26.2 rearrangement has characteristic dysmegakaryopoiesis including increased small monolobated or hypolobated megakaryocytes. 14 However, in some cases of our study, the morphologic features of megakaryocytes were different from the characteristic dysmegakaryopoiesis in myelodysplastic syndrome/acute myeloid leukemia. Instead, they may show small monolobated morphology typical for myelodysplastic syndrome or large atypical megakaryocytes typical for myeloproliferative neoplasms. One potential explanation for the discrepancy is that some megakaryocytes retain their atypical morphology of Like patients with other myeloid neoplasms harboring 3q26.2 rearrangement, patients with classical Philadelphia chromosome-negative myeloproliferative neoplasms in our study were resistant to conventional chemotherapy and had a short overall survival. There is no consensus on the best therapy for these patients. Stem cell transplantation is thought to be the only potential therapy to cure the diseases. 25, 26 However, no patients in our study survived long enough to receive stem cell transplantation due to the rapid disease deterioration. Search for new potential therapies is warranted for these patients. In theory, targeted therapies that block EVI1 functions may prevent the disease progression. In addition, mutations in RAS signaling pathway (NRAS, KRAS, PTPN11, and NF1) were identified in EVI1-rearranged acute myeloid leukemia. Groschel, et al 22, 27 found high rates of mutations in RAS signaling pathway (NRAS, KRAS and NF1) in acute myeloid leukemia, blast phase of chronic myeloid leukemia and myelodysplastic syndrome patients with 3q26.2 rearrangement. Thus, it is reasonable to speculate that novel drugs interfering with RAS signaling might be effective treating these patients resistant to the conventional chemotherapy. 22, 27, 28 With regard to the prognostic models for myeloproliferative neoplasms, several prognostic models have been developed to predict the outcome of myelofibrosis since the first publication of the IPSS in 2009. 29 In our study, we did not use the IPSS score for patients with 3q26.2 rearrangement because the IPSS can be used only at the time of initial diagnosis of myeloproliferative neoplasms. In contrast, DIPSS and DIPSS-plus can be used at any given time point during the disease course of myelofibrosis. 5, 18, 30 The actual overall survival after the emergence of 3q26.2 rearrangement in our study is markedly shorter than the expected overall survival predicted by DIPSS. This indicates that the DIPSS score underestimates the poor prognosis in these patients. The DIPSS-plus score, which takes into account karyotypical abnormalities, platelet count, and transfusion status, reclassified patients with intermediate-1/2 risk by the DIPSS scores to intermediate-2 or high-risk category. Although the DIPSS-plus has a superior prognostic indication, the expected overall survival predicted by this model still understimates the dismal prognosis of patients with 3q26.2 rearrangement.
Of note, to compare the impact of 3q26.2 rearrangement vs other karyotypical abnormalities in disease progression and patient outcome, we identified a control group of a total of 180 patients with classical Philadelphia chromosome-negative myeloproliferative neoplasms, including 25 patients with essential thrombocythemia, 127 with primary myelofibrosis and 28 with polycythemia vera. These patients developed karyotypical abnormalities other than 3q26.2 rearrangement and the exact time of emergence of the karyotypical abnormalities was available for us. A total of 45/180 (25%) patients in the control group developed blast crisis at emergence of the karyotypical abnormalities or later compared with 12/15 (80%) patients with 3q26.2 rearrangement (P o 0.0001). The median survival time of patients in the control group from the emergence of the karyotypical abnormalities was 35 months vs 3 months in those with 3q26.2 rearrangement (P o 0.0001).
In summary, 3q26.2 rearrangement is a fatal event in the clinical course of patients with classical Philadelphia chromosome-negative myeloproliferative neoplasms that is often associated with a rapid disease progression, blastic transformation, and a dismal outcome. These patients have no response to any current chemotherapy regimens, and new therapeutic options including targeted therapy are needed.
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